Serum and Urine Galectin-3 as a Diabetic Nephropathy Predictive Biomarker
DOI:
https://doi.org/10.32007/jfacmedbaghdad1982Keywords:
Galectin-3, microalbuminuria, Albumin/creatinine ratio; , diabetic nephropathy; , diabetes mellitus.Abstract
Background: Diabetic nephropathy (DN) is a major cause of end-stage kidney impairment in patients with type 2 diabetes mellitus (DM). Galectin-3 has been linked to the development of numerous pathological conditions. There is currently little information about the interaction between DN and galectin-3.
Objectives: The use of serum and urine galectin-3 as a unique forecasting diagnostic in DN patients.
Methods: The present study was conducted in Baquba Teaching Hospital, Specialized Consultation clinic, Internal Medicine Department, and Iraq Specialized Laboratory in Baquba, Diyala governorate between October 2021 and February 2022 on 150 individuals with type 2 diabetes. Individuals were divided into three groups: Fifty individuals with an albumin/creatinine ratio (ACR) of 30 mg/g (normoalbuminuria), 50 patients with an ACR of 30-300 mg/g (microalbuminuria), and 50 healthy individuals with an ACR of 30 mg/g (healthy control). All subjects were subjected to extensive clinical assessment and examination and laboratory investigations (HbA1c, serum creatinine, serum galectin-3 as well as ACR, which was calculated based on urine test).
Results: The mean concentrations of serum and urine galectin-3 levels were noticeably greater in those with microalbuminuria than normoalbuminuria, (11.2±3.61), (7.0±2.17) as compared to (9.0± 1.32) (7.6± 1.72) respectively. Serum Galectin-3 showed a high sensitivity (100%) and specificity (86%). Urine Galectin-3 sensitivity was (98%) and specificity (78%).
Conclusion: This study has shown that serum and urine galectin-3 are important predictors of DN development in people with type 2 diabetes.
Received: Sept. 2022
Revised: Oct. 2022
Accepted: June 2025
Published Online April 2025
Published: July 2025
Downloads
References
Satirapoj B, Adler SG. Prevalence and management of diabetic nephropathy in Western countries. Kidney Dis (Basel) 2015;1(1):61-70. https://doi.org/10.1159/000382028
2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532-2539.
https://doi.org/10.1001/jama.2011.861
3. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. https://doi.org/10.2215/CJN.11491116
4. American Diabetes Association 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Supplement 1):S124-S138.
https://doi.org/10.2337/dc19-S011
5. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176.
https://doi.org/10.2337/diacare.28.1.164
6. Sacks DB, Arnold M, Bakris GL, Bruns DE , Horvath AR, Kirkman MS , et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34(6):e61. https://doi.org/10.2337/dc11-9998
7. Murussi M, Baglio P, Gross JL, Silveiro SP. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Diabetes Care. 2002;25(6):1101-110.
https://doi.org/10.2337/diacare.25.6.1101
8. Jh A, Cho YM, Hg Y, Jang HC, Park KS, Kim SY, et al. The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. J Korean Med Sci. 2009;24:S75-81.
https://doi.org/10.3346/jkms.2009.24.S1.S75
9. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1):1-150.
10. Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL, Arnoys EJ. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta. 2010;1800(2):181-189.
https://doi.org/10.1016/j.bbagen.2009.07.005
11. Newlaczyl AU, Yu LG. Galectin-3 - a jack-of-all-trades in cancer. Canc Lett. 2011;313(2):123-128.
https://doi.org/10.1016/j.canlet.2011.09.003
12. Nio-Kobayashi J. Tissue- and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and disease. Anat Sci Int. 2017;92(1):25-36.
https://doi.org/10.1007/s12565-016-0366-6
13. Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology. 2015;25(2):136-150.
https://doi.org/10.1093/glycob/cwu111
14. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014;52(10):1413-1423.
https://doi.org/10.1515/cclm-2014-0187
15. Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351(2):336-343. https://doi.org/10.1124/jpet.114.218370
16. Díaz-Alvarez L and Ortega E. The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens. Mediators Inflamm. 2017;2017(8):1-10.
https://doi.org/10.1155/2017/9247574
17. de Oliveira FL, Gatto M, Bassi N, Bassi N, Luisetto R, Ghirardello A, Punzi L, et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood) 2015;240(8):1019-1028.
https://doi.org/10.1177/1535370215593826
18. Chen SC, Kuo PL. The role of galectin-3 in the kidneys. Int J Mol Sci. 2016;17(4):234.
https://doi.org/10.3390/ijms17040565
19. Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in renal pathology: more than just an innocent bystander. Am J Nephrol. 2016;43(5):305-317.
https://doi.org/10.1159/000446376
20. Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, et al. Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. J Am Soc Nephrol. 2015;26(9):2213-2221.
https://doi.org/10.1681/ASN.2014010093
21.O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013;24(9):1470-1477.
https://doi.org/10.1681/ASN.2012090909
22. Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, et al. New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". Nutrition, Metabolism and Cardiovascular Diseases. 2019 Nov 1;29(11):1127-50. https://doi.org/10.1016/j.numecd.2019.07.017
23.Hodeib H, Hagras MM, Abdelhai D, Watany MM, Selim A, Tawfik MA, et al. Galectin-3 as a prognostic biomarker for diabetic nephropathy. Diabetes, metabolic syndrome and obesity: targets and therapy. 2019;12:325. https://doi.org/10.2147/DMSO.S194410
24. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Invest. 2015;38(5):527-533.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Dalia M. Saleh, Manal K. Rasheed , Ali R. Hameed
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Creative Commons Attribution 4.0 International license..
